A Study of Safety & Blood Levels of IDL-2965 in Healthy Subjects and Patients With a Special Type of Pulmonary Fibrosis

Summary

The purpose of this study is to test the safety and tolerability of the drug candidate IDL-2965 and to see how it is absorbed, processed, and removed by the body.

Timeline

Start

2019-04-16

Primary completion

2020-03-29

Completion

2020-03-29

Outcome

Outcome not reported

Stopped: “Due to development challenges associated with the SARS-CoV-2 pandemic and emerging nonclinical data”

Drugs

Indications